Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial

Nutrition and Diabetes

Volumn 6, Issue 8, 2016, Pages

  van der Aa, M P ^a   Elst, M A J ^a   van de Garde, E M W ^a   van Mil, E G A H ^b   Knibbe, C A J ^a   van der Vorst, M M J ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN;

ADOLESCENT; BODY COMPOSITION; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EXERCISE; FEMALE; HUMAN; INSULIN RESISTANCE; LIFESTYLE; MALE; OBESITY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; BODY COMPOSITION; CHILD; DOUBLE-BLIND METHOD; EXERCISE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIFE STYLE; MALE; METFORMIN; OBESITY; TREATMENT OUTCOME;

EID: 85001077644     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/NUTD.2016.37     Document Type: Article

References (35)

1. Ahluwalia N, Dalmasso P, Rasmussen M, Lipsky L, Currie C, Haug E et al. Trends in overweight prevalence among 11-, 13-and 15-year-olds in 25 countries in Europe, Canada and USA from 2002 to 2010. Eur J Public Health 2015; 25 (Suppl 2): 28–32.
2. van Jaarsveld CH, Gulliford MC. Childhood obesity trends from primary care electronic health records in England between 1994 and 2013: population-based cohort study. Arch Dis Child 2015; 100: 214–219.
3. Levy-Marchal C, Arslanian S, Cutfield W, Sinaiko A, Druet C, Marcovecchio ML et al. Insulin resistance in children: consensus, perspective, and future directions. J Clin Endocrinol Metab 2010; 95: 5189–5198.
4. Burrows RA, Leiva LB, Weisstaub G, Lera LM, Albala CB, Blanco E et al. High HOMA-IR, adjusted for puberty, relates to the metabolic syndrome in overweight and obese Chilean youths. Pediatr Diabetes 2011; 12 (3 Pt 2): 212–218.
5. Pankow JS, Jacobs Jr DR, Steinberger J, Moran A, Sinaiko AR. Insulin resistance and cardiovascular disease risk factors in children of parents with the insulin resistance (metabolic) syndrome. Diabetes Care 2004; 27: 775–780.
6. Cruz ML, Shaibi GQ, Weigensberg MJ, Spruijt-Metz D, Ball GD, Goran MI. Pediatric obesity and insulin resistance: chronic disease risk and implications for treatment and prevention beyond body weight modification. Annu Rev Nutr 2005; 25: 435–468.
7. Oberbach A, Neuhaus J, Inge T, Kirsch K, Schlichting N, Bluher S et al. Bariatric surgery in severely obese adolescents improves major comorbidities including hyperuricemia. Metabolism 2014; 63: 242–249.
8. Arrigo T, Gitto E, Ferrau V, Munafo C, Alibrandi A, Marseglia GL et al. Effect of weight reduction on leptin, total ghrelin and obestatin concentrations in prepubertal children. J Biol Regul Homeost Agents 2012; 26(1 Suppl): S95–S103.
9. Gronbaek H, Lange A, Birkebaek NH, Holland-Fischer P, Solvig J, Horlyck A et al. Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children. J Pediatr Gastroenterol Nutr 2012; 54: 223–228.
10. Chiavaroli V, Giannini C, D'Adamo E, de Giorgis T, Torello M, D’Orazio N et al. Weight loss in obese prepubertal children: the influence of insulin resistance. Endocr Res 2013; 38: 48–57.
11. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 4059–4067.
12. Fazeli Farsani S, Souverein PC, Overbeek JA, van der Vorst MM, Knibbe CA, Herings RM et al. Long term trends in oral antidiabetic drug use among children and adolescents in the Netherlands. Br J Clin Pharmacol 2015; 80: 294–303.
13. Hsia Y, Dawoud D, Sutcliffe AG, Viner RM, Kinra S, Wong IC. Unlicensed use of metformin in children and adolescents in the UK. Br J Clin Pharmacol 2012; 73: 135–139.
14. Kostev K, Richter H. Unlicensed use of metformin in children and adolescents in Germany and France. Br J Clin Pharmacol 2012; 73: 307–308.
15. Park MH, Kinra S, Ward KJ, White B, Viner RM. Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 2009; 32: 1743–1745.
16. Wilson DM, Abrams SH, Aye T, Lee PD, Lenders C, Lustig RH et al. Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Ado-lesc Med 2010; 164: 116–123.
17. van der Aa MP, Elst MA, van Mil EG, Knibbe CA, van der Vorst MM. METFORMIN: an efficacy, safety and pharmacokinetic study on the short-term and long-term use in obese children and adolescents-study protocol of a randomized controlled study. Trials 2014; 15: 207.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
19. Kolotkin RL, Zeller M, Modi AC, Samsa GP, Quinlan NP, Yanovski JA et al. Assessing weight-related quality of life in adolescents. Obesity (Silver Spring) 2006; 14: 448–457.
20. Wouters EJM, Geenen R, Kolotkin RL, Vingerhoets AJJM. Met lichaamsgewicht samenhangende kwaliteit van leven bij adolescenten. Psychometrische kwaliteit van de Nederlandse vertaling van de IWQOL-Kids. Tijdschr Kindergeneeskd 2010; 78: 119–125.
21. Burgert TS, Duran EJ, Goldberg-Gell R, Dziura J, Yeckel CW, Katz S et al. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes 2008; 9: 567–576.
22. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305: 1659–1668.
23. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001; 107: E55.
24. Kay JP, Alemzadeh R, Langley G, D’Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001; 50: 1457–1461.
25. Kendall D, Vail A, Amin R, Barrett T, Dimitri P, Ivison F et al. Metformin in obese children and adolescents: the MOCA trial. J Clin Endocrinol Metab 2013; 98: 322–329.
26. Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. JPediatr2008; 152: 817–822.
27. Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, Yap F et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endo-crinol Metab 2006; 91: 2074–2080.
28. Wiegand S, l’Allemand D, Hubel H, Krude H, Burmann M, Martus P et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. Eur J Endocrinol 2010; 163: 585–592.
29. Yanovski JA, Krakoff J, Salaita CG, McDuffie JR, Kozlosky M, Sebring NG et al. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes 2011; 60: 477–485.
30. Ali S, Fonseca V. Overview of metformin: special focus on metformin extended release. Expert Opin Pharmacother 2012; 13: 1797–1805.
31. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metfor-min tablets: results of a retrospective cohort study. Curr Med Res Opin 2004; 20: 565–572.
32. Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, Lewin A. Efficacy, toler-ability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006; 29: 759–764.
33. Diaz Cisneros FJ, Rivera Cisneros AE, Lopez Martinez MG, Garcia Gonzalez MR, Lopez Ortega H. Effects of an aerobic exercise program and diet on body composition and cardiovascular function in obese persons. Arch Inst Cardiol Mex 1986; 56: 527–533.
34. Antuna-Puente B, Faraj M, Karelis AD, Garrel D, Prud'homme D, Rabasa-Lhoret R et al. HOMA or QUICKI: Is it useful to test the reproducibility of formulas? Diabetes Metab 2008; 34: 294–296.
35. Henriquez S, Jara N, Bunout D, Hirsch S, de la Maza MP, Leiva L et al. Variability of formulas to assess insulin sensitivity and their association with the Matsuda index. Nutr Hosp 2013; 28: 1594–1598.